These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28153778)

  • 21. Liver-Directed AAV8 Booster Vaccine Expressing
    Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
    Front Immunol; 2021; 12():612910. PubMed ID: 34248928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
    Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM
    PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies.
    Pandey AK; Reddy KS; Sahar T; Gupta S; Singh H; Reddy EJ; Asad M; Siddiqui FA; Gupta P; Singh B; More KR; Mohmmed A; Chitnis CE; Chauhan VS; Gaur D
    Infect Immun; 2013 Feb; 81(2):441-51. PubMed ID: 23184525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum.
    Aza-Conde J; Reyes C; Suárez CF; Patarroyo MA; Patarroyo ME
    Biochem Biophys Res Commun; 2021 Jan; 534():86-93. PubMed ID: 33316544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoaffinity purification of polyepitope proteins against Plasmodium falciparum with chicken IgY specific to their C-terminal epitope tag.
    Qu JX; Lin YH; Ma RS; Wang H
    Protein Expr Purif; 2011 Feb; 75(2):225-9. PubMed ID: 20940054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein.
    Ord RL; Caldeira JC; Rodriguez M; Noe A; Chackerian B; Peabody DS; Gutierrez G; Lobo CA
    Malar J; 2014 Aug; 13():326. PubMed ID: 25135070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys.
    Douglas AD; Baldeviano GC; Lucas CM; Lugo-Roman LA; Crosnier C; Bartholdson SJ; Diouf A; Miura K; Lambert LE; Ventocilla JA; Leiva KP; Milne KH; Illingworth JJ; Spencer AJ; Hjerrild KA; Alanine DG; Turner AV; Moorhead JT; Edgel KA; Wu Y; Long CA; Wright GJ; Lescano AG; Draper SJ
    Cell Host Microbe; 2015 Jan; 17(1):130-9. PubMed ID: 25590760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris.
    Faber BW; Remarque EJ; Kocken CH; Cheront P; Cingolani D; Xhonneux F; Jurado M; Haumont M; Jepsen S; Leroy O; Thomas AW
    Vaccine; 2008 Nov; 26(48):6143-50. PubMed ID: 18804135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions.
    Mukhopadhyay E; Brod F; Angell-Manning P; Green N; Tarrant RD; Detmers FJ; Bolam EJ; Baleanu IN; Hobson M; Whale G; Morris SJ; Ashfield R; Gilbert SC; Jin J; Draper SJ; Moyle SP; Berrie EL; Hill AVS
    Biotechnol Bioeng; 2022 Oct; 119(10):2784-2793. PubMed ID: 35822551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on Immunogenicity and Antigenicity of Baculovirus-Expressed Binding Region of Plasmodium falciparum EBA-140 Merozoite Ligand.
    Zerka A; Rydzak J; Lass A; Szostakowska B; Nahorski W; Wroczyńska A; Myjak P; Krotkiewski H; Jaskiewicz E
    Arch Immunol Ther Exp (Warsz); 2016 Apr; 64(2):149-56. PubMed ID: 26439848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein.
    Beiss V; Spiegel H; Boes A; Kapelski S; Scheuermayer M; Edgue G; Sack M; Fendel R; Reimann A; Schillberg S; Pradel G; Fischer R
    Biotechnol Bioeng; 2015 Jul; 112(7):1297-305. PubMed ID: 25615702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01.
    Payne RO; Milne KH; Elias SC; Edwards NJ; Douglas AD; Brown RE; Silk SE; Biswas S; Miura K; Roberts R; Rampling TW; Venkatraman N; Hodgson SH; Labbé GM; Halstead FD; Poulton ID; Nugent FL; de Graaf H; Sukhtankar P; Williams NC; Ockenhouse CF; Kathcart AK; Qabar AN; Waters NC; Soisson LA; Birkett AJ; Cooke GS; Faust SN; Woods C; Ivinson K; McCarthy JS; Diggs CL; Vekemans J; Long CA; Hill AV; Lawrie AM; Dutta S; Draper SJ
    J Infect Dis; 2016 Jun; 213(11):1743-51. PubMed ID: 26908756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a process for large scale production of PfRH5 in E. coli expression system.
    Raghuwanshi AS; Kumar A; Raghuwanshi N; Singh SK; Singh AK; Tripathi U; Kaviraj S; Singh S
    Int J Biol Macromol; 2021 Oct; 188():169-179. PubMed ID: 34364940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.
    Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW
    Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion.
    Singh AP; Puri SK; Chitnis CE
    Mol Biochem Parasitol; 2002 Apr; 121(1):21-31. PubMed ID: 11985860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli.
    Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P
    Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose.
    Kaslow DC; Shiloach J
    Biotechnology (N Y); 1994 May; 12(5):494-9. PubMed ID: 7764708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine.
    Singh SK; Roeffen W; Mistarz UH; Chourasia BK; Yang F; Rand KD; Sauerwein RW; Theisen M
    Microb Cell Fact; 2017 May; 16(1):97. PubMed ID: 28569168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.